Simplify

Simplify drug asset development by migrating the majority of combination product activities to a dedicated product platform. This architecture is built to manage the scaling of multiple variants and adapt effortlessly to changes in the drug product or transitions between study phases.

• Standardize 90% of your drug development documentation within an intelligent platform, so the project team only needs to address the remaining 10%.
• Leverage the same platform structure to efficiently reuse and update your complete documentation across sequential clinical phases.
• Save efforts and resources by covering common ground activities among all drug assets once in a platform.

• Minimize regulatory and development overhead by tailoring requirements to the specific needs of each clinical study phase.
• Reduce front-end workload by utilizing components and documentation that have already been fully pre-developed.
• Employ proven bracketing approaches to reduce efforts in design verification.

• Mitigate delay and effort risks associated with drug changes by utilizing a platform that covers a broad range of specification.
• Transition between vials, syringes, and injectors with ease, as the platform pre-manages all necessary component interfaces.
• Depend on the unified platform definitions and requirements already aligned across your entire partner network.